Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Call Transcripts
Kiniksa Pharmaceuticals International, plc's Latest Earnings Call - June 9, 2026
In the Q2 2026 earnings call, Kiniksa Pharmaceuticals (KNSA:US) reported a significant increase in revenue guidance for the fiscal year, raising it from $900-$920 million to $930-$945 million. This upward revision reflects strong commercial growth driven by ARCALYST in recurrent pericarditis, which is on track to exceed $1 billion in revenue next year. The company also highlighted ongoing clinical developments, particularly with KPL-387, which is in Phase II/III trials, and KPL-1161, expected to enter Phase I by year-end.
Reported metrics
| Metric | Value |
|---|---|
| Revenue Guidance | $930-$945 million (beat) |
| Total Prescribers | 4,550 (positive) |
| Cash Reserves | $468 million (positive) |
| Market Penetration | 18% (positive) |
| New Prescribers | Highest ever in Q1 (positive) |
| Expected Phase III Start | End of 2026 (positive) |
Guidance from management
Kiniksa anticipates continued strong growth in ARCALYST sales, with guidance raised for 2026. They expect to initiate the Phase III study for KPL-387 by the end of this year, further advancing their pipeline.
What management said
Yes. So maybe I'll start by just saying we clearly monitor everything. We really kind of established and have been building this marketplace to help patients suffering from recurrent pericarditis. We have other ongoing clinical trials within this disease, which are also of the interleukin-1 alpha beta inhibition mechanism as well. We think that is incredibly important. And we acknowledge that ARCALYST has a very, ver...
What analysts pressed on
Analysts expressed concerns about the competitive landscape, particularly regarding new entrants in the recurrent pericarditis market. There are questions about how Kiniksa plans to maintain its market position amidst increasing competition.
Main topics on the call
- Increased Revenue Guidance — Kiniksa raised its full-year revenue guidance from $900-$920 million to $930-$945 million, indicating robust growth in ARCALYST sales. Management stated, "we really have line of sight to blockbuster status for this drug....
- Strong Commercial Performance — The company reported the highest number of new prescribers and patient enrollments for ARCALYST since its launch, with over 4,550 total prescribers identified. This reflects a growing acceptance and understanding of the ...
- Pipeline Development — Kiniksa is advancing its pipeline with KPL-387 in Phase II/III studies and KPL-1161 expected to enter Phase I by year-end. Management noted, "we anticipate moving into the Phase III clinical study by the end of this year...
- Market Penetration Insights — Management indicated that ARCALYST has penetrated approximately 18% of the target patient population with 2 or more recurrences, suggesting significant room for growth. They emphasized the need to educate more prescriber...
Read the full Kiniksa Pharmaceuticals International, plc transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc (KNSA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 41 calls on record spanning January 13, 2020 to July 28, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 41 Kiniksa Pharmaceuticals International, plc earnings call transcripts on record, spanning January 13, 2020 to July 28, 2026. Based on this history, Kiniksa Pharmaceuticals International, plc reports quarterly. The most recent call on file is dated July 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- KNSA
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 41
- First call
- January 13, 2020
- Most recent
- July 28, 2026
- Reporting cadence
- quarterly